Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its ...
Everest Medicines presented eravacycline data at IDWeek 2024, showing broad antimicrobial activity against Carbapenem-resistant Acinetobacter baumannii and consistent efficacy against Gram-positive and Gram-negative bacteria. Eravacycline, a fluorocycline, is approved for complicated intra-abdominal infections and has shown high treatment effectiveness.
© Copyright 2024. All Rights Reserved by MedPath